Comparable stake leader
T. Rowe Price Investment Management, Inc.
SEC ownership of CYTOKINETICS INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001061983.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- CYTK on Nasdaq
- Parsed ownership sources
-
13F and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
T. Rowe Price Investment Management, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
T. Rowe Price Investment Management, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001061983
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of CYTOKINETICS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
T. Rowe Price Investment ...
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
Lead comparable stake: 14%
13D/G row: T. Rowe Price Investment Management, Inc.
Showing 1-8 of 50 holder rows.
Quick read
T. Rowe Price Investment Management, Inc. leads the comparable SEC ownership view at 14%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens T. Rowe Price Investment Management, Inc.'s linked filing trail.
Comparable ownership
Top 5
T. Rowe Price Investment Manageme...
14%
VANGUARD CAPITAL MANAGEMENT LLC
5.2%
WELLINGTON MANAGEMENT GROUP LLP
5.1%
STATE STREET CORP
4.7%
FMR LLC
3.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13F
13D/G
Company
|
14%
from 13D/G
|
$1,594,629,000
18,718,498 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
13D/G
Company · Vanguard Capital Management
|
5.2%
from 13D/G
|
$521,151,103
6,117,515 shares
|
— | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
5.1%
|
$608,978,073
7,116,724 shares
|
$0 | 30 Jun 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
4.7%
from 13D/G
|
$553,243,709
6,494,233 shares
|
— | 30 Jun 2026 |
| FMR LLC |
13D/G
13F
Company
|
3.9%
|
$447,127,030
5,248,580 shares
|
-$501,481,150 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
14%
|
$1,711,838,738
20,094,362 shares
|
— | 30 Jun 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
4.8%
|
$571,778,157
6,711,799 shares
|
— | 30 Jun 2026 |
| Avoro Capital Advisors LLC |
13F
Company
|
3.6%
|
$425,949,915
4,999,999 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$43,822,780.
Buys
$0
Insiders: 0
Sells
$43,822,780
Insiders: 9
Net
-$43,822,780
Shares: -640,574
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 640,574
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 149,909 | $0 | $11,991,128 | -$11,991,128 |
| 3-6 | 0 | 264,772 | $0 | $17,770,693 | -$17,770,693 |
| 6-9 | 0 | 151,385 | $0 | $9,817,152 | -$9,817,152 |
| 9-12 | 0 | 74,508 | $0 | $4,243,805 | -$4,243,805 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to CYTOKINETICS INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
Robert I. Blum
Net 12M change
-$43,822,780
Latest report
18 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Robert I. Blum | President & CEO, Director | $29,356,363 | -$9,702,097 | -25% | Mixed | 10 Aug 2026 |
| David Cragg | Chief HR & Admin Officer | $12,476,231 | Mixed | 07 Mar 2022 | ||
| Fady Ibraham Malik | EVP Research & Development | $11,668,849 | -$4,352,750 | -27% | Filing P/S | 18 Aug 2026 |
| Mark A. Schlossberg | SVP - Legal & General Counsel | $8,419,479 | Mixed | 15 Mar 2022 | ||
| Ching Jaw | SVP Finance & CFO | $7,111,711 | Mixed | 06 Mar 2023 | ||
| Jeffrey Hessekiel | Chief Legal & Admin Officer | $6,760,470 | Mixed | 15 Mar 2026 | ||
| Henderson John T. | Director | $6,682,558 | -$2,078,525 | -24% | Median | 15 Jul 2026 |
| Sung Lee | EVP, Chief Financial Officer | $5,550,171 | -$5,695,856 | -51% | Filing P/S | 01 Jul 2026 |
| Andrew Callos | EVP, Chief Commercial Officer | $4,677,373 | -$15,318,894 | -77% | Filing P/S | 30 Jul 2026 |
| Wendell Wierenga | Director | $3,029,611 | -$1,881,925 | -38% | Median | 15 Jul 2026 |
| Nancy Wysenski | Director | $2,895,778 | Median | 15 Jul 2026 | ||
| L. Patrick Gage | Director | $2,506,270 | Mixed | 08 Nov 2021 | ||
| Brett A. Pletcher | EVP, Chief Legal Officer | $1,897,596 | Mixed | 30 Aug 2024 | ||
| Robert Arthur Harrington | Director | $1,868,387 | -$248,261 | -12% | Median | 15 Jul 2026 |
| Muna Bhanji | Director | $1,737,453 | Mixed | 27 May 2026 | ||
| Sandford D. Smith | Director | $1,530,777 | Mixed | 02 Jan 2024 | ||
| Santo J. Costa | Director | $1,341,266 | Mixed | 15 May 2024 | ||
| Wendall Wierenga | Director | $1,229,433 | Mixed | 15 Jul 2025 | ||
| B. Lynne Parshall | Director | $1,169,278 | -$1,000,100 | -46% | Filing P/S | 01 Jun 2026 |
| Robert Wong | VP, Chief Accounting Officer | $960,919 | Mixed | 03 Dec 2024 |
Recent insider transactions for CYTOKINETICS INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -2.22% | $265,370 | $75.82 | -3,500 | 153,902 | 18 Aug 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Options Exercise | 2.27% | 3,500 | 157,402 | 18 Aug 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -10.3% | -3,500 | 30,386 | 18 Aug 2026 | Direct | ||
| Robert I. Blum | CYTK | Common Stock | Sale | -1.95% | $575,700 | $76.76 | -7,500 | 377,820 | 10 Aug 2026 | Direct |
| Robert I. Blum | CYTK | Common Stock | Options Exercise | 1.99% | 7,500 | 385,320 | 10 Aug 2026 | Direct | ||
| Robert I. Blum | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -4.18% | -7,500 | 171,745 | 10 Aug 2026 | Direct | ||
| Andrew Callos | CYTK | Common Stock | Sale | -19.3% | $1,118,320 | $79.88 | -14,000 | 58,555 | 30 Jul 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Options Exercise | 23.9% | 14,000 | 72,555 | 30 Jul 2026 | Direct | ||
| Andrew Callos | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -58.3% | -14,000 | 10,000 | 30 Jul 2026 | Direct | ||
| Robert I. Blum | CYTK | Common Stock | Sale | -1.95% | $606,525 | $80.87 | -7,500 | 377,820 | 27 Jul 2026 | Direct |
| Robert I. Blum | CYTK | Common Stock | Options Exercise | 1.99% | 7,500 | 385,320 | 27 Jul 2026 | Direct | ||
| Robert I. Blum | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -4.02% | -7,500 | 179,245 | 27 Jul 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -2.22% | $282,065 | $80.59 | -3,500 | 153,902 | 21 Jul 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Options Exercise | 2.27% | 3,500 | 157,402 | 21 Jul 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -9.36% | -3,500 | 33,886 | 21 Jul 2026 | Direct | ||
| Nancy Wysenski | CYTK | Common Stock | Award | 0.22% | 75 | 33,992 | 15 Jul 2026 | Direct | ||
| Wendell Wierenga | CYTK | Common Stock | Award | 0.21% | 75 | 35,563 | 15 Jul 2026 | Direct | ||
| Edward M. Kaye MD | CYTK | Common Stock | Award | 1.47% | 151 | 10,434 | 15 Jul 2026 | Direct | ||
| Henderson John T. | CYTK | Common Stock | Award | 0.35% | 272 | 78,360 | 15 Jul 2026 | Direct | ||
| Robert Arthur Harrington | CYTK | Common Stock | Award | 0.69% | 151 | 21,932 | 15 Jul 2026 | Direct | ||
| James M. Daly | CYTK | Common Stock | Award | 4.66% | 151 | 3,390 | 15 Jul 2026 | Direct | ||
| Robert I. Blum | CYTK | Common Stock | Options Exercise | 1.98% | 7,490 | 385,310 | 13 Jul 2026 | Direct | ||
| Robert I. Blum | CYTK | Common Stock | Sale | -1.95% | $615,150 | $82.02 | -7,500 | 377,820 | 13 Jul 2026 | Direct |
| Robert I. Blum | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -3.86% | -7,490 | 186,745 | 13 Jul 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -2.22% | $303,170 | $86.62 | -3,500 | 153,902 | 07 Jul 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Options Exercise | 2.27% | 3,500 | 157,402 | 07 Jul 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -8.56% | -3,500 | 37,386 | 07 Jul 2026 | Direct | ||
| Robert I. Blum | CYTK | Common Stock | Sale | -1.95% | $636,900 | $84.92 | -7,500 | 377,830 | 01 Jul 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Sale | -20.4% | $1,287,000 | $85.80 | -15,000 | 58,555 | 01 Jul 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Options Exercise | 25.6% | 15,000 | 73,555 | 01 Jul 2026 | Direct | ||
| Andrew Callos | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -38.5% | -15,000 | 24,000 | 01 Jul 2026 | Direct | ||
| Sung Lee | CYTK | Common Stock | Sale | -1.73% | $97,622 | $87.79 | -1,112 | 63,221 | 01 Jul 2026 | Direct |
| Sung Lee | CYTK | Common Stock | Options Exercise | 1.76% | 1,112 | 64,333 | 01 Jul 2026 | Direct | ||
| Sung Lee | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -4% | -1,112 | 26,709 | 01 Jul 2026 | Direct | ||
| Sung Lee | CYTK | Common Stock | Sale | -4.72% | $266,390 | $85.00 | -3,134 | 63,221 | 29 Jun 2026 | Direct |
| Sung Lee | CYTK | Common Stock | Options Exercise | 4.96% | 3,134 | 66,355 | 29 Jun 2026 | Direct | ||
| Sung Lee | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -6.5% | -2,758 | 39,681 | 29 Jun 2026 | Direct | ||
| Sung Lee | CYTK | Incentive Stock Option (Right to Buy) | Options Exercise | -4.17% | -376 | 8,640 | 29 Jun 2026 | Direct | ||
| Sung Lee | CYTK | Common Stock | Sale | -38% | $3,187,479 | $82.30 | -38,730 | 63,221 | 24 Jun 2026 | Direct |
| Sung Lee | CYTK | Common Stock | Options Exercise | 61.3% | 38,730 | 101,951 | 24 Jun 2026 | Direct | ||
| Sung Lee | CYTK | Incentive Stock Option (Right to Buy) | Options Exercise | -33.3% | -3,005 | 6,011 | 24 Jun 2026 | Direct | ||
| Sung Lee | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -56.2% | -35,725 | 27,821 | 24 Jun 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -2.22% | $278,285 | $79.51 | -3,500 | 153,902 | 23 Jun 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Options Exercise | 2.27% | 3,500 | 157,402 | 23 Jun 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -7.89% | -3,500 | 40,886 | 23 Jun 2026 | Direct | ||
| Robert I. Blum | CYTK | Common Stock | Sale | -1.91% | $528,450 | $70.46 | -7,500 | 385,330 | 15 Jun 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -2.22% | $237,930 | $67.98 | -3,500 | 153,902 | 09 Jun 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Options Exercise | 2.27% | 3,500 | 157,402 | 09 Jun 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -7.31% | -3,500 | 44,386 | 09 Jun 2026 | Direct | ||
| Edward M. Kaye MD | CYTK | Common Stock | Sale | -22.2% | $223,172 | $76.09 | -2,933 | 10,283 | 01 Jun 2026 | Direct |
* marks a reported price that did not pass the local price check.